NeuroLogica Corporation announced today at the XIV World Congress of Neurological Surgery in Boston, MA, receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its portable high resolution SPECT system: inSPira HD (www.inspirahd.com).
The inSPira HD is a battery powered, high resolution, portable SPECT designed primarily for brain imaging. Its unique capabilities provide the highest quality SPECT images wherever needed, including the Clinic, ICU, OR and Emergency Department. inSPira HD is capable of imaging any radioisotope energies between 80 – 200 keV for clinical applications such as Epilepsy, Parkinson’s, Stroke and Alzheimer's Dementia. Features such as high resolution, convenience, portability, and versatility set the inSPira HD apart from any other SPECT imaging system available today.
Traditional systems whose basic principles have been around since the 1960’s continue to suffer from poor spatial and contrast resolution. This has led to the term “fuzzy” imaging with 5-10mm spatial resolution in any one axis. The inSPira HD is revolutionary because it presents an entirely new method of SPECT detection, acquisition, and reconstruction which has been designed to approach 3mm spatial resolution.
“The medical community demands and deserves higher spatial and contrast resolution,” says Dr. Eric M. Bailey, President and Chief Executive Officer of NeuroLogica. “And we are pleased to provide that capability at a price point that makes sense in today’s economic environment. The inSPira HD is an entirely new type of SPECT imaging and will play a key role in the treatment of neurological diseases going forward.”